Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, June 14 '25)

Image
By G.M.

 


    Antiviral Res

  1. CHANG CW, Oswal N, Murugan M, Goldgirsh K, et al
    A novel cellular tool for screening human pan-coronavirus antivirals.
    Antiviral Res. 2025 Jun 10:106212. doi: 10.1016/j.antiviral.2025.106212.
    PubMed         Abstract available


    Clin Infect Dis

  2. LEE R, Kim N, Kim WB, Im KI, et al
    Effectiveness and safety of Autologous Virus-Specific T Cell Therapy for Persistent COVID-19 in People with Immunocompromise: A Clinical Trial Study.
    Clin Infect Dis. 2025 Jun 10:ciaf302. doi: 10.1093.
    PubMed         Abstract available

  3. SUDNIK P, Walsh EE, Branche AR, Islam M, et al
    Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV.
    Clin Infect Dis. 2025 Jun 12:ciaf310. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  4. WEE LE, Ho RWL, Lim JT, Chiew CJ, et al
    Long-term multi-systemic sequelae post-hospitalization for Omicron COVID-19 versus influenza: a retrospective cohort study.
    Int J Infect Dis. 2025 Jun 9:107946. doi: 10.1016/j.ijid.2025.107946.
    PubMed         Abstract available


    J Infect

  5. BUTLER CC, Hobbs FDR, Little P, Richards D, et al
    Ivermectin and COVID-19.
    J Infect. 2025 Jun 8:106530. doi: 10.1016/j.jinf.2025.106530.
    PubMed        


    J Med Virol

  6. PEREZ-COZAR F, Cal-Sabater P, Rybakowska P, Arribas-Rodriguez E, et al
    High-Dimensional Immunophenotyping of Post-COVID-19 and Post-Influenza Patients Reveals Persistent and Specific Immune Signatures After Acute Respiratory Infection.
    J Med Virol. 2025;97:e70435.
    PubMed         Abstract available

  7. FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Gil-Crujera A, Gomez-Sanchez SM, et al
    ACE1 rs1799752 Polymorphism Is not Associated With the Presence of Post-COVID-19 Condition.
    J Med Virol. 2025;97:e70438.
    PubMed        


    J Virol

  8. COTTIGNIES-CALAMARTE A, Marteau F, He F, Belouzard S, et al
    Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.
    J Virol. 2025 Jun 12:e0039425. doi: 10.1128/jvi.00394.
    PubMed         Abstract available

  9. LIU M, Aryal B, Niu X, Wang Q, et al
    Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
    J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
    PubMed         Abstract available

  10. MORGAN AL, Vu MN, Zhou Y, Lokugamage KG, et al
    The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2.
    J Virol. 2025 Jun 10:e0046725. doi: 10.1128/jvi.00467.
    PubMed         Abstract available

  11. FOSTER CSP, Walker GJ, Jean T, Wong M, et al
    Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution.
    J Virol. 2025 Jun 9:e0036325. doi: 10.1128/jvi.00363.
    PubMed         Abstract available

  12. LOKUGAMAGE KG, Zhou Y, Alvarado RE, Plante JA, et al
    Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection.
    J Virol. 2025 Jun 12:e0209124. doi: 10.1128/jvi.02091.
    PubMed         Abstract available

  13. LI C, Shi Y, Xie C, Duan K, et al
    GSDMD and GSDME exhibit distinct roles in enteric coronavirus PDCoV-induced pyroptosis and inflammatory responses.
    J Virol. 2025 Jun 12:e0187624. doi: 10.1128/jvi.01876.
    PubMed         Abstract available

  14. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
    Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
    J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
    PubMed         Abstract available


    JAMA

  15. GOSTIN LO, Reiss D, Offit PA
    Changed Recommendations for COVID-19 Vaccines for Children and Pregnant Women: A Failure of Process, Policy, and Science.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.10658.
    PubMed        

  16. ZETTLER PJ, Cha S, Despres S, Lurie P, et al
    FDA Review of Novavax's COVID-19 Vaccine-Regulatory Integrity and Deviations From Standard Practice.
    JAMA. 2025 Jun 9. doi: 10.1001/jama.2025.9898.
    PubMed        


    Lancet Infect Dis

  17. URIU K, Okumura K, Uwamino Y, Chen L, et al
    Virological characteristics of the SARS-CoV-2 NB.1.8.1 variant.
    Lancet Infect Dis. 2025 Jun 6:S1473-3099(25)00356.
    PubMed        

  18. GUO C, Yu Y, Liu J, Jian F, et al
    Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1.
    Lancet Infect Dis. 2025 Jun 5:S1473-3099(25)00308.
    PubMed        


    N Engl J Med

  19. MCINTYRE L, Fergusson D, McArdle T, English S, et al
    A Crossover Trial of Hospital-Wide Lactated Ringer's Solution versus Normal Saline.
    N Engl J Med. 2025 Jun 12. doi: 10.1056/NEJMoa2416761.
    PubMed         Abstract available


    Zhonghua Jie He He Hu Xi Za Zhi

  20. CHEN T, Xu ZJ
    [Recomment of the correctly understand and standardize the use of terms and concepts related to interstitial lung disease].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:589-591.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

Stability of #influenza viruses in the #milk of #cows and #sheep

By G.M.
Abstract In late 2023, H5N1 high pathogenicity avian influenza (HPAIV) started circulating in dairy cattle in the USA . High viral titres were detected in milk from infected cows , raising concerns about onwards human infections . Although pasteurisation was shown to effectively inactivate influenza viruses in milk, unpasteurised milk still poses a risk of infection, both from occupational exposure in dairies and from the consumption of raw milk. We therefore assessed how long influenza viruses could remain infectious for in milk without heat inactivation. We examined the stability of a panel of influenza viruses in milk , including a contemporary H5N1 HPAIV and a variety of other influenza A and D viruses. We incubated viruses in cows' milk under laboratory conditions : at room temperature to simulate exposure in dairies and at 4°C to simulate exposure to refrigerated raw milk. Following an isolated report of H5N1 viral RNA being detected in milk from a sheep in the UK , we also c...
Post a Comment
Read more »

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

By G.M.
Abstract We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA . Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article ____
Post a Comment
Read more »